ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 0.2012 USD -1.85% Market Closed
Market Cap: 9.5m USD

ESSA Pharma Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ESSA Pharma Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Free Cash Flow
-$20.9m
CAGR 3-Years
9%
CAGR 5-Years
-3%
CAGR 10-Years
-8%
Theratechnologies Inc
TSX:TH
Free Cash Flow
-$3.1m
CAGR 3-Years
40%
CAGR 5-Years
10%
CAGR 10-Years
-23%
Repare Therapeutics Inc
NASDAQ:RPTX
Free Cash Flow
-$70.1m
CAGR 3-Years
N/A
CAGR 5-Years
-80%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Free Cash Flow
$119.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Free Cash Flow
-$253.3m
CAGR 3-Years
-42%
CAGR 5-Years
-70%
CAGR 10-Years
-31%
Spectral Medical Inc
TSX:EDT
Free Cash Flow
-CA$9.3m
CAGR 3-Years
2%
CAGR 5-Years
-80%
CAGR 10-Years
0%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
8.9m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
Not Available

See Also

What is ESSA Pharma Inc's Free Cash Flow?
Free Cash Flow
-20.9m USD

Based on the financial report for Jun 30, 2025, ESSA Pharma Inc's Free Cash Flow amounts to -20.9m USD.

What is ESSA Pharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-8%

Over the last year, the Free Cash Flow growth was 12%. The average annual Free Cash Flow growth rates for ESSA Pharma Inc have been 9% over the past three years , -3% over the past five years , and -8% over the past ten years .

Back to Top